ADAM-9 modulators
The invention provides the identification and characterization of a disease and cancer-associated antigen, KID24. The invention also provides modulators of KID24, including a family of monoclonal antibodies that bind to antigen KID24, and methods of diagnosing and treating various human cancers and diseases with KID24.
1. A method for delivering a chemotherapeutic agent to a cancer cell that over-expresses KID24 comprising administering a composition comprising an anti-KID24 antibody associated with the chemotherapeutic agent, wherein said anti-KID24 antibody is an antibody expressed by the cell line having deposit number ATCC No. PTA# 5174, or a progeny thereof, or a monoclonal antibody that specifically binds to the same epitope on KID24 as said anti-KID24 antibody expressed by the cell line having deposit number ATCC No. PTA# 5174 specifically binds.
2. The method of claim 1 , wherein said anti-KID24 antibody is an antibody expressed by the cell line having deposit number ATCC No. PTA# 5174, or a progeny thereof.
3. The method of claim 1 , wherein said cancer cell is selected from the group consisting of a cancer cell from a breast cancer, a colon cancer, a colorectal cancer, a kidney cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a stomach cancer, and a bone cancer.
4. A method of inhibiting growth of a cancer cell that over-expresses KID24 in an individual comprising administering to said individual an effective amount of a composition comprising an anti-KID24 antibody associated with a chemotherapeutic agent, wherein said anti-KID24 antibody is an antibody expressed by the cell line having deposit number ATCC No. PTA# 5174, or a progeny thereof, or a monoclonal antibody that specifically binds to the same epitope on KID24 as said anti-KID24 antibody expressed by the cell line having deposit number ATCC No. PTA# 5174 specifically binds.
5. The method of claim 4 , wherein said anti-KID24 antibody is an antibody expressed by the cell line having deposit number ATCC No. PTA# 5174, or a progeny thereof.
6. The method of claim 4 , wherein said cancer cell is selected from the group consisting of a cancer cell from a breast cancer, a colon cancer, a colorectal cancer, a kidney cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a stomach cancer, and a bone cancer.
7. A method for inhibiting the development of a metastasis comprising a cancer cell that over-expresses KID24 in an individual who has had a primary tumor, comprising administration of a pharmaceutical composition comprising a therapeutically effective dose of:
(A) a chimeric antibody comprising the variable regions of the light chain and the heavy chain of an anti-KID24 antibody that is expressed by the cell line having deposit number ATCC No. PTA# 5174, or a chimeric antibody that specifically binds to the same epitope on KID24 as said anti-KID24 antibody expressed by the cell line having deposit number ATCC No. PTA# 5174 specifically binds, or an antigen-binding fragment thereof; or
(B) a humanized antibody comprising the three CDRs from the light chain and the three CDRs from the heavy chain of the anti-KID24 antibody that is expressed by the cell line having deposit number ATCC No. PTA# 5174, or an antigen-binding fragment thereof;
together with a pharmaceutically acceptable carrier.
8. The method of claim 7 , wherein said administered pharmaceutical composition comprises said chimeric antibody.
9. The method of claim 7 , wherein said administered pharmaceutical composition comprises said humanized antibody.
10. The method of claim 7 , wherein the pharmaceutical composition comprises an additional diagnostic or therapeutic moiety.
11. The method of claim 7 , wherein said primary tumor has previously been treated by surgery, radiation or chemotherapy.
12. The method of claim 7 , wherein said cancer cell is selected from the group consisting of a cancer cell from a breast cancer, a colon cancer, a colorectal cancer, a kidney cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a stomach cancer, and a bone cancer.
13. A method of treating cancer, comprising administration of a pharmaceutical composition to an individual having cancer comprising a cancer cell that over-expresses KID24, said pharmaceutical composition comprising a therapeutically effective dose of:
(A) a chimeric antibody comprising the variable regions of the light chain and the heavy chain of an anti-KID24 antibody that is expressed by the cell line having deposit number of ATCC No. PTA# 5174, or a chimeric antibody that specifically binds to the same epitope on KID24 as said anti-KID24 antibody expressed by the cell line having deposit number ATCC No. PTA# 5174 specifically binds, or an antigen-binding fragment thereof; or
(B) a humanized antibody comprising the three CDRs from the light chain and the three CDRs from the heavy chain of the anti-KID24 antibody that is expressed by the cell line having deposit number of ATCC No. PTA# 5174, or an antigen-binding fragment thereof;
together with a pharmaceutically acceptable carrier.
14. The method of claim 13 , wherein said administered pharmaceutical composition comprises said chimeric antibody.
15. The method of claim 13 , wherein said administered pharmaceutical composition comprises said humanized antibody.
16. The method of claim 13 , wherein the pharmaceutical composition comprises an additional diagnostic or therapeutic moiety.
17. The method of claim 13 , wherein said cancer has previously been treated by surgery, radiation or chemotherapy.
18. The method of claim 13 , wherein said cancer is selected from the group consisting of a cancer cell from a breast cancer, a colon cancer, a colorectal cancer, a kidney cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a stomach cancer, and a bone cancer.